Registration Dossier

Administrative data

Description of key information

A read-across is proposed with Ethoxylated Bisphenol A diacrylate. The potential of acute toxicity of Ethoxylated Bisphenol A diacrylate was evaluated in two studies, one by oral route and one by dermal route. No mortalities was showed in both studies; the oral and dermal LD50 were higher than 2000 mg/kg in rats. No data is available by inhalation.
The same results are available on 2 moles ethoxylated bisphenol A dimethacrylate (read-across).

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Study period:
31 May 2012 - 16 July 2012
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: Compliant to GLP and testing guidelines; adequate consistence between data, comments and conclusions.
Qualifier:
according to
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
Deviations:
no
Qualifier:
according to
Guideline:
EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
Deviations:
no
GLP compliance:
yes (incl. certificate)
Test type:
acute toxic class method
Limit test:
yes
Species:
rat
Strain:
Sprague-Dawley
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: breeder: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: approximately 8 weeks old on the day of treatment
- Mean body weight at study initiation: 218 g (range: 203 g to 226 g)
- Fasting period before study: yes, during the night before treatment
- Housing: polycarbonate cages with stainless steel lids
- Diet: SSNIFF R/M-H pelleted diet (free access)
- Water: tap water filtered with a 0.22 µm filter (free access)
- Acclimation period: at least 5 days before treatment.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50 ± 20%
- Air changes (per hr): approximately 12 cycles/hour of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12 h/12 h.

IN-LIFE DATES: 12 June 2012 to 10 July 2012.
Route of administration:
oral: gavage
Vehicle:
corn oil
Details on oral exposure:
VEHICLE
- Concentration in vehicle: 30 and 200 mg/mL
- Justification for choice of vehicle: The vehicle used in this study was selected from the results of solubility assays performed by the CiToxLAB France Pharmacy.
In the absence of recommendation from the Sponsor, the solubility assay first started at the concentration of 200 mg/mL, and the first choice vehicle was drinking water treated by reverse osmosis. As unsatisfactory solubility of the test item was obtained in this vehicle (i.e. heterogeneous emulsion or suspension at the concentration of 200 mg/mL was obtained), another vehicle was chosen from the following organic solvents (in order of preference): 0.5% methylcellulose aqueous solution and corn oil. A homogenous suspension was obtained at the concentration of 200 mg/mL in corn oil.
- Maximum dose-volume applied: 20 mL/kg

DOSAGE PREPARATION (if unusual):
The test item was administered as a homogenous suspension in the vehicle. The test item was mixed with the required quantity of vehicle.
Dose formulations preparations were prepared by the CiToxLAB France Pharmacy extemporaneously on the day of each administration.
The dose formulations were stored in a well ventilated place, at a temperature < 45°C, and delivered to the study room in brown flasks.

CLASS METHOD (if applicable):
- Rationale for the selection of the starting dose:
The starting dose-level was selected in agreement with the Sponsor, based on the following rationale: since no relevant toxicity data are available for the estimation of a lethal dose-level and any existing data were taken into account by the Sponsor, the starting dose-level was 300 mg/kg for animal welfare reasons.
Doses:
300 and 2000 mg/kg.
No. of animals per sex per dose:
3 females per treatment step.
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Clinical observations: frequently during the hours following treatment; then, at least once a day.
- Body weight: just before treatment on day 1; then on days 8 and 15.
- Necropsy of survivors performed: yes (macroscopic).
Statistics:
No
Sex:
female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Remarks on result:
other: No mortality on 6 females treated with 2000 mg/kg
Mortality:
No unscheduled deaths occurred during the study.
Clinical signs:
Piloerection was observed between 1 and 3 hours and/or 4 hours after treatment in 2/3 females treated at 300 mg/kg. There were no clinical signs observed at the dose-level of 2000 mg/kg.
Body weight:
When compared to CiToxLAB France historical control data, a slightly lower body weight gain was noted in 3/6 females treated at 2000 mg/kg between day 1 and day 8 (+22 g to +36 g vs. +44 ± 4.2 g in control data base) and between day 8 and day 15 (+10 g and +13 g vs. +20 ± 5.7 g in control data base).
A slightly lower body weight gain was also noted in 2/3 females treated at 300 mg/kg between day 1 and day 8 (+28 g and +38 g vs. +44 ± 4.2 g in control data base) and between day 8 and day 15 (+5 g and +12 g vs. +20 ± 5.7 g in control data base).
Gross pathology:
The few macroscopic findings noted (red discoloration in the thymus in two females from group 3) at the end of the observation period were of those commonly recorded in the Sprague-Dawley rat and none were considered to be related to the test item administration.
Other findings:
no
Interpretation of results:
not classified
Remarks:
Migrated information Criteria used for interpretation of results: other: CLP Regulation
Conclusions:
The oral LD50 of the test item was higher than 2000 mg/kg in rats.
Therefore, the test item is not classified as toxic or harmful by oral route according to the criteria of CLP Regulation.
Executive summary:

The objective of this study was to evaluate the potential acute toxicity of the test item following a single oral administration (gavage) to rats.

This study was performed according to the international guidelines (OECD No. 423 and Council Regulation No. 440/2008 of 30 May 2008, Part B.1tris) andin compliance with the principles of Good Laboratory Practices.

 

Methods

The test item was administered once by oral route (gavage) to three groups of three fasted female Sprague-Dawley rats under a dosage-volume of 10 mL/kg. The test item was prepared in corn oil.

Since no relevant toxicity data were available for the estimation of a lethal dose-level and any existing data have been taken into account by the Sponsor, the starting dose-level was 300 mg/kg for ethical reasons. After the first assay, the next higher dose-level of 2000 mg/kg was tested. Then, as no toxicity was observed at this higher dose-level, the results were confirmed in other females by using the same dose‑level.

Each animal was observed at least once a day for mortality and clinical signs for 15 days. Body weight was recorded on day 1 and then on days 8 and 15.

On completion of the observation period, the animals were sacrificed and then submitted for a macroscopic post-mortem examination.Macroscopic lesions were preservedin buffered formalin thendestroyed at the finalization of the study report as no microscopic examination was performed.

Results

No unscheduled deaths occurred during the study.

Piloerection was observed between 1 and 3 hours and/or 4 hours after treatment in 2/3 females treated at 300 mg/kg. There were no clinical signs observed at the dose-level of 2000 mg/kg.

When compared to CiToxLAB France historical control data, a slightly lower body weight gain was noted in females treated at 300 or 2000 mg/kg between day 1 and day 15.

The test item administration did not induce any macroscopic changes.

Conclusion

The oral LD50 of the test item was higher than 2000 mg/kg in rats.

Therefore, the test item is not classified as toxic or harmful by oral route according to the criteria of CLP Regulation.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
discriminating dose
2 000 mg/kg bw
Quality of whole database:
Both studies are reliable with a klimisch score of 1 or 2.

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Study period:
31 May 2012 - 06 July 2012
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: Compliant to GLP and testing guidelines; adequate consistence between data, comments and conclusions.
Qualifier:
according to
Guideline:
OECD Guideline 402 (Acute Dermal Toxicity)
Deviations:
no
Qualifier:
according to
Guideline:
EU Method B.3 (Acute Toxicity (Dermal))
Deviations:
no
GLP compliance:
yes (incl. certificate)
Test type:
standard acute method
Limit test:
yes
Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: breeder: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: approximately 8 weeks old on the day of treatment
- Mean body weight at study initiation: the males had a mean body weight of 358 g (range: 348 g to 366 g) and the females had a mean body weight of 241 g (range: 223 g to 254 g)
- Fasting period before study: yes, during the night before treatment
- Housing: the animals were housed by five from the same sex and group in polycarbonate cages with stainless steel lids
- Diet: SSNIFF R/M-H pelleted diet (free access)
- Water: tap water filtered with a 0.22 µm filter (free access)
- Acclimation period: for a period of 5 or 8 days before treatment.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50 ± 20%
- Air changes (per hr): approximately 12 cycles/hour of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12 h/12 h.

IN-LIFE DATES: 19 June 2012 to 06 July 2012.
Type of coverage:
semiocclusive
Vehicle:
unchanged (no vehicle)
Details on dermal exposure:
TEST SITE
- Area of exposure: 10% of body surface, dorsal site
- Type of wrap if used: hydrophilic gauze pad + adhesive hypoallergenic aerated semi-occlusive dressing + restraining bandage.

REMOVAL OF TEST SUBSTANCE
- Removal of dressing: 24h post-exposure
- Washing: at 24h post-exposure, with a moistened cotton pad.

Duration of exposure:
1 single exposure of 24 hours
Doses:
2000 mg/kg.
No. of animals per sex per dose:
5 females (group 1) and 5 males (group 2).
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Clinical observations: frequently during the hours following treatment; then, at least once a day.
- Body weight: just before treatment on day 1; then on days 8 and 15.
- Necropsy of survivors performed: yes (macroscopic).
Statistics:
no
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Remarks on result:
other: (no mortality)
Mortality:
No unscheduled deaths occurred during the study.
Clinical signs:
No clinical signs indicative of systemic toxicity were observed in any animals.
No cutaneous reactions were observed in any animals.
Body weight:
When compared to historical control data, a lower body weight gain was noted in 4/5 males (30 to 38 g vs. 45 ± 4.0 g in control data base) and in 3/5 females (11 to 19 g vs. 36 ± 12.3 g in control data base) between day 1 and day 8. The body weight gain returned to normal thereafter.
Gross pathology:
Several up to 0.3 cm black discolored foci were noted in the lung of one male treated at 2000 mg/kg with Ethoxylated bisphenol A diacrylate.
A 0.3 cm black discolored area was also noted in the lung (left lobe) of one male in the same group.
Despite the incidence of this finding in the male group (2/5 rats affected), a relationship to treatment was considered to be doubtful. Such changes may indeed occur as agonic changes.
Other findings:
no
Interpretation of results:
not classified
Remarks:
Migrated information Criteria used for interpretation of results: other: CLP Regulation
Conclusions:
The dermal LD50 of the test item was higher than 2000 mg/kg in rats.
Therefore, the test item is not classified as toxic or harmful by dermal route according to the criteria of CLP Regulation.
Executive summary:

The objective of this study was to evaluate the potential toxicity of the test item following a single dermal application to rats.

This study was performed according to the international guidelines (OECD No. 402 and Council Regulation No. 440/2008 of 30 May 2008, Part B.3) and in compliance with the principles of Good Laboratory Practice.

 

Methods

The test item was applied in its original form to the skin of five female then five male Sprague‑Dawley rats at the dose-level of 2000 mg/kg. The application site was covered by a semi‑occlusive dressing for 24 hours.

Each animal was observed at least once a day for mortality and clinical signs for 15 days. From day 2, any local reactions at the treatment site were also noted. Body weight was recorded on day 1 and then on days 8 and 15.

On completion of the observation period, the animals were sacrificed and then submitted for a macroscopic post-mortem examination.Macroscopic lesions were preserved in buffered formalin then destroyed at the finalization of the study report as no microscopic examination was performed.

 

Results

No unscheduled deaths and no clinical signs indicative of systemic toxicity were observed in any animals.

No cutaneous reactions were observed in any animals.

When compared to CiToxLAB France historical control data, a lower body weight gain was noted in 4/5 males and in 3/5 females between day 1 and day 8.

There were no macroscopic changes related to the test item treatment.

Conclusion

The dermal LD50 of the test item was higher than 2000 mg/kg in rats.

Therefore, the test item is not classified as toxic or harmful by dermal route according to the criteria of CLP Regulation.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
discriminating dose
2 000 mg/kg bw
Quality of whole database:
Both studies are reliable with a klimisch score of 1.

Additional information

Oral acute toxicity (read-across)

In the key study (Silvano 2012), Ethoxylated Bisphenol A diacrylate was administered once by oral route (gavage) to fasted female Sprague-Dawley rats under a dosage-volume of 10 mL/kg (OECD 423 study). The test item was prepared in corn oil. No unscheduled deaths occurred during the study. Piloerection was observed between 1 and 3 hours and/or 4 hours after treatment in 2/3 females treated at 300 mg/kg. There were no clinical signs observed at the dose-level of 2000 mg/kg. When compared to historical control data, a slightly lower body weight gain was noted in females treated at 300 or 2000 mg/kg between day 1 and day 15. The test item administration did not induce any macroscopic changes. The oral LD50 of Ethoxylated Bisphenol A diacrylate was higher than 2000 mg/kg in rats.

Dermal acute toxicity (read-across)

In the key study (Silvano 2012), Ethoxylated Bisphenol A diacrylate was applied in its original form to the skin of five female then five male Sprague‑Dawley rats at the dose-level of 2000 mg/kg (OECD 402 study). The application site was covered by a semi‑occlusive dressing for 24 hours. No unscheduled deaths and no clinical signs indicative of systemic toxicity were observed in any animals. No cutaneous reactions were observed in any animals. When compared to historical control data, a lower body weight gain was noted in 4/5 males and in 3/5 females between day 1 and day 8. There were no macroscopic changes related to the test item treatment. The dermal LD50 of Ethoxylated Bisphenol A diacrylate

was higher than 2000 mg/kg in rats.

Justification for selection of acute toxicity – oral endpoint
A read-across is proposed for this endpoint with Ethoxylated bisphenol A diacrylate and 2 moles Ethoxylated bisphenol A dimethacrylate. The study on Ethoxylated bisphenol A diacrylate is flagged as key study because of the composition of target substance (Ethoxylated bisphenol A dimethacrylate).

Justification for selection of acute toxicity – dermal endpoint
A read-across is proposed for this endpoint with Ethoxylated bisphenol A diacrylate and 2 moles Ethoxylated bisphenol A dimethacrylate. The study on Ethoxylated bisphenol A diacrylate is flagged as key study because of the composition of target substance (Ethoxylated bisphenol A dimethacrylate).

Justification for classification or non-classification

Toxicity by oral or dermal route is very low (LD50> 2000 mg/kg), no classification is expected for this endpoint according to the Regulation EC n°1272/2008 and the Directive 67/548/EEC.